Kent Hawryluk, MBX Biosciences CEO
September 9, 2024 07:35 AM EDT
Financing
Startups

MBX seeks $114M IPO to com­pete with As­cendis and get a long-act­ing GLP-1/GIP pro­drug in­to the clin­ic

Kyle LaHucik

Senior Reporter

MBX Bio­sciences is the lat­est IPO con­tender af­ter sub­mit­ting its pitch for a $114 mil­lion Nas­daq de­but, which will go to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times